In situ amorphization has been recently introduced to overcome the challenges of drug load, stability and manufacturing of ASDs. In situ amorphization can overcome storage stability issues of ASDs and allows for higher drug loadings (up to 50 wt%) than what is dictated by the thermodynamic solubility limit of the drug in the polymer at storage temperature since storage times can be kept short. Amorphization and ASD formation take place in the final dosage form either directly after tablet manufacturing or before administration to the patient, e.g. at hospital pharmacies. The tablet for in situ amorphization is produced by established pharmaceutical tableting protocols such as direct compaction of a crystalline drug in a polymer mixture. The ASD is then formed in situ by exposing the tablet to a radiation source, e.g. microwave or laser. This is a time-and temperature-dependent process, whereby the radiation increases the tablet temperature and the drug dissolves in the polymer at temperatures above the glass transition temperature (Tg) of the polymer. Amorphization by microwave radiation requires excipients, such as glycerol or water in the tablets. Large amounts (approx. 20 wt%) of the enabling excipients have to be added to reach complete amorphization, which hampers the mechanical properties of the tablet. The laser-induced approach uses plasmonic nanoparticles (Ag) as the enabling excipient and only requires as low as 0.1 wt% of them in the tablets. However, the penetration depth of the laser in the tablet is limited and not uniform, making the scale-up difficult. Furthermore, the use of plasmonic nanoparticles maybe toxic upon repeated administration to patients due to their dose dependent toxicity. Thus, there is a need to identify other effective and safe in situ amorphization excipients.